S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.92 (-1.75%)
AAPL   172.40 (-0.78%)
MSFT   313.39 (-2.61%)
META   300.94 (-1.92%)
GOOGL   132.43 (-1.30%)
AMZN   124.72 (-3.66%)
TSLA   246.53 (-2.02%)
NVDA   435.17 (-2.82%)
NIO   8.61 (-2.05%)
BABA   84.57 (-2.27%)
AMD   100.08 (-3.09%)
T   14.79 (+0.82%)
F   12.07 (-1.95%)
MU   67.83 (-0.19%)
CGC   0.68 (-6.82%)
GE   107.77 (-0.94%)
DIS   79.54 (-2.61%)
AMC   7.86 (-3.56%)
PFE   33.90 (-0.12%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
Top-Rated StocksTop-Rated
NASDAQ:DXCM

DexCom (DXCM) Stock Forecast, Price & News

$90.94
-3.61 (-3.82%)
(As of 10/3/2023 ET)
Compare
Today's Range
$90.24
▼
$94.36
50-Day Range
$86.06
▼
$132.38
52-Week Range
$85.31
▼
$139.55
Volume
3.01 million shs
Average Volume
2.95 million shs
Market Capitalization
$35.27 billion
P/E Ratio
105.74
Dividend Yield
N/A
Price Target
$132.06
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

DexCom MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
45.2% Upside
$132.06 Price Target
Short Interest
Healthy
4.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.65mentions of DexCom in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$1.28 M Sold Last Quarter
Proj. Earnings Growth
29.27%
From $1.23 to $1.59 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.40 out of 5 stars

Medical Sector

11th out of 976 stocks

Surgical & Medical Instruments Industry

3rd out of 99 stocks

See Top Rated MarketRank™ Stocks Here

DXCM stock logo

About DexCom (NASDAQ:DXCM) Stock

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Price History

DXCM Stock News Headlines

September 5, 2023 | marketbeat.com
Why Analysts Say GE's Healthcare Spinoff Has $20 Upside (DXCM)
General Electric’s spinoff, GE HealthCare Technologies Inc., is delivering some impressive results and has growth opportunities well worth tuning in to.
October 3, 2023 | americanbankingnews.com
DexCom (NASDAQ:DXCM) Price Target Lowered to $115.00 at Citigroup
October 3, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
October 3, 2023 | americanbankingnews.com
Short Interest in DexCom, Inc. (NASDAQ:DXCM) Declines By 5.3%
October 3, 2023 | americanbankingnews.com
Citigroup Lowers DexCom (NASDAQ:DXCM) Price Target to $115.00
October 2, 2023 | finance.yahoo.com
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
October 1, 2023 | americanbankingnews.com
DexCom (NASDAQ:DXCM) PT Lowered to $98.00
September 29, 2023 | benzinga.com
(DXCM) - Analyzing DexCom's Short Interest
October 3, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
September 29, 2023 | finance.yahoo.com
Buy this Tech Stock on the Dip in October for 50% Upside?
September 29, 2023 | finance.yahoo.com
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.
September 27, 2023 | finance.yahoo.com
DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital
September 25, 2023 | americanbankingnews.com
DexCom, Inc. (NASDAQ:DXCM) Director Steven Robert Pacelli Sells 411 Shares
September 22, 2023 | benzinga.com
DexCom Unusual Options Activity For September 22
September 21, 2023 | marketwatch.com
DexCom Inc. stock falls Thursday, underperforms market
September 21, 2023 | finance.yahoo.com
Dexcom Canada and RxFood Corporation Partner on Industry-Leading, AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management and Personalized Therapeutic Nutrition
September 21, 2023 | finance.yahoo.com
Weight-Loss Drugs Like Wegovy Are Bad News for These Stocks
September 20, 2023 | benzinga.com
Massive Insider Trade At DexCom
September 20, 2023 | finance.yahoo.com
3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 Years
September 19, 2023 | finance.yahoo.com
Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program
September 18, 2023 | forbes.com
Will DexCom Stock Recover To Its Pre-Inflation Shock Highs Of $160?
September 15, 2023 | fool.com
Why DexCom Stock Dove by 5% Today
September 12, 2023 | finance.yahoo.com
DexCom (DXCM) Rises 7% in One Week: What's Driving It?
September 12, 2023 | msn.com
Why DexCom May Be Up To 40% Undervalued
September 12, 2023 | finance.yahoo.com
Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France
September 11, 2023 | benzinga.com
$100 Invested In This Stock 15 Years Ago Would Be Worth $6,500 Today
September 11, 2023 | finance.yahoo.com
Is DexCom, Inc. (NASDAQ:DXCM) A High Quality Stock To Own?
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Company Calendar

Last Earnings
7/27/2023
Today
10/03/2023
Next Earnings (Confirmed)
10/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
CIK
1093557
Web
www.dexcom.com
Phone
(858) 200-0200
Fax
858-200-0201
Employees
7,600
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$132.06
High Stock Price Forecast
$160.00
Low Stock Price Forecast
$98.00
Forecasted Upside/Downside
+45.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.86
Trailing P/E Ratio
105.62
Forward P/E Ratio
73.85
P/E Growth
1.77
Net Income
$341.20 million
Net Margins
11.18%
Pretax Margin
15.74%
Return on Equity
22.01%
Return on Assets
8.06%

Debt

Debt-to-Equity Ratio
1.16
Current Ratio
2.42
Quick Ratio
2.21

Sales & Book Value

Annual Sales
$2.91 billion
Price / Sales
12.11
Cash Flow
$1.27 per share
Price / Cash Flow
71.24
Book Value
$5.52 per share
Price / Book
16.45

Miscellaneous

Outstanding Shares
387,870,000
Free Float
386,282,000
Market Cap
$35.23 billion
Optionable
Optionable
Beta
1.13

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Kevin Ronald Sayer (Age 65)
    Exec. Chairman, CEO & Pres
    Comp: $2.22M
  • Mr. Jereme M. SylvainMr. Jereme M. Sylvain (Age 43)
    Exec. VP, CFO & Chief Accounting Officer
    Comp: $841.14k
  • Mr. Jacob Steven LeachMr. Jacob Steven Leach (Age 45)
    Exec. VP & COO
    Comp: $994.13k
  • Mr. Girish Naganathan (Age 46)
    Exec. VP & CTO
    Comp: $423.92k
  • Mr. Michael Jon BrownMr. Michael Jon Brown (Age 53)
    Exec. VP & Chief Legal Officer
    Comp: $954.46k
  • Mr. Shelly Ramasamy Selvaraj (Age 64)
    Sr. VP & Chief Information Officer
  • Mr. Sean Christensen
    Director of Corp. Affairs & Head of Investor Relations
  • Mr. Matthew Dolan (Age 42)
    Exec. VP of Strategy, Corp. Devel. & Dexcom Labs
  • Ms. Sadie M. SternMs. Sadie M. Stern (Age 48)
    Exec. VP & Chief HR Officer
  • Mr. Steven R. PacelliMr. Steven R. Pacelli (Age 51)
    Exec. VP & MD of Dexcom Ventures

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













DXCM Stock - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

What is DexCom's stock price forecast for 2023?

14 equities research analysts have issued 12-month price objectives for DexCom's shares. Their DXCM share price forecasts range from $98.00 to $160.00. On average, they expect the company's stock price to reach $132.06 in the next twelve months. This suggests a possible upside of 45.4% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2023?

DexCom's stock was trading at $113.24 on January 1st, 2023. Since then, DXCM stock has decreased by 19.8% and is now trading at $90.83.
View the best growth stocks for 2023 here.

Are investors shorting DexCom?

DexCom saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 16,030,000 shares, a decline of 5.3% from the August 31st total of 16,920,000 shares. Based on an average trading volume of 3,630,000 shares, the short-interest ratio is currently 4.4 days.
View DexCom's Short Interest.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our DXCM earnings forecast.

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, October 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, July, 27th. The medical device company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.12. The medical device company had revenue of $871.30 million for the quarter, compared to the consensus estimate of $841.16 million. DexCom had a net margin of 11.18% and a trailing twelve-month return on equity of 22.01%. The firm's revenue for the quarter was up 25.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.17 earnings per share.
Read the conference call transcript.

What ETFs hold DexCom's stock?

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS).

When did DexCom's stock split?

Shares of DexCom split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $90.83.

How much money does DexCom make?

DexCom (NASDAQ:DXCM) has a market capitalization of $35.23 billion and generates $2.91 billion in revenue each year. The medical device company earns $341.20 million in net income (profit) each year or $0.86 on an earnings per share basis.

How many employees does DexCom have?

The company employs 7,600 workers across the globe.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.

This page (NASDAQ:DXCM) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -